NASD · Healthcare · Biotechnology · USA
Precigen Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Precigen is a biopharmaceutical company developing precision medicines targeting immuno-oncology, autoimmune disorders, and infectious diseases. The company leverages proprietary technology platforms including AdenoVerse immunotherapy and UltraCAR-T to construct and deliver gene programs for treating complex diseases. Precigen received FDA approval for Papzimeos, an adenoviral vector-based immunotherapy for recurrent respiratory papillomatosis, and maintains a clinical pipeline of additional candidates.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Precigen Inc stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: not even its current assets cover what it owes.
17 more funds hold it; the full list is part of the paid plan.
137 more in this industry show a wider margin of safety.
We do not publish a verdict on PGEN yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-20 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.